Search

everythinglearnresearchcommunity

for

Search:↓

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Lasers can help reduce skin side effects from cancer treatment.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Certain gene variations might increase the risk of a hair loss condition in Koreans.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Gefitinib can cause scalp skin issues and permanent hair loss.

Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

EGFR is crucial for preventing hair follicle inflammation and hair loss.

EGFR inhibitors can cause skin issues, and managing these is important for treatment success.

Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.

EGF receptors are crucial for skin cell growth and decrease with age.

Understanding EGFR's role in skin is crucial for better treatments and managing side effects.

Erlotinib can cause excessive eyelash growth.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.